How long do you treat recurrent classical Hodgkin lymphoma with brentuximab/nivolumab if the patient does not want to proceed to BMT?

The phase 1/2 study of BV/nivolumab combination aimed to maximize response with a goal to proceed with autologous SCT. In the trial protocol, patients would receive 4 cycles of therapy (Blood 2018).

If a patient changed their mind and does not want autologous SCT, then I would drop BV (assuming they ...